Advertisement
Singapore markets open in 40 minutes

  • Straits Times Index

    3,265.95
    +1.42 (+0.04%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • Dow

    39,387.76
    +331.36 (+0.85%)
     

  • Nasdaq

    16,346.26
    +43.46 (+0.27%)
     

  • Bitcoin USD

    62,904.22
    +1,705.93 (+2.79%)
     

  • CMC Crypto 200

    1,353.16
    +53.06 (+4.08%)
     

  • FTSE 100

    8,381.35
    +27.30 (+0.33%)
     

  • Gold

    2,353.30
    +13.00 (+0.56%)
     

  • Crude Oil

    79.62
    +0.36 (+0.45%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • Nikkei

    38,361.79
    +287.81 (+0.76%)
     

  • Hang Seng

    18,537.81
    +223.91 (+1.22%)
     

  • FTSE Bursa Malaysia

    1,601.22
    -3.53 (-0.22%)
     

  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     

  • PSE Index

    6,542.46
    -116.72 (-1.75%)
     

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

IN8bio, Inc
·1-min read
IN8bio, Inc
IN8bio, Inc

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Details of the oral presentation are as follows:

Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression

Session Type: In-Person Oral Presentation

Session Title: Novel Production Platforms

Abstract Number: 282

ADVERTISEMENT

Location: Ballroom 2

Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET

Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at https://in8bio.com once the presentation concludes.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.

Corporate Contact:
IN8bio, Inc.
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com

Investors
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com